Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Effepharm (Shanghai) Co. Ltd. focuses its patent activity in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action being processed by the USPTO. This single action is assigned to 1 distinct examiner and is housed within 1 distinct art unit. This indicates a focused current prosecution presence.
Hoi Yan Nmn Lee is the busiest examiner for the company, managing 1 pending office action. Since there is only 1 pending action for the entire portfolio, this examiner is responsible for all current interactions. The placement within 1 art unit in the biotechnology sector suggests the company is pursuing a specific pharmaceutical or biological innovation. Practitioners only need to account for the specific tendencies of this 1 examiner and 1 art unit at this stage. This concentrated activity allows for a dedicated approach to overcoming any rejections raised by the examiner in this specialized field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, HOI YAN NMN | 1 | 38.5% | +74.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19262831 | AMORPHOUS FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR | LEE, HOI YAN NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19262831 | AMORPHOUS FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR | LEE, HOI YAN NMN | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19262831 | AMORPHOUS FORM OF REDUCED ß-NICOTINAMIDE MONONUCLEOTIDE CALCIUM SALT, AND PREPARATION METHOD AND USE THEREFOR | LEE, HOI YAN NMN | 1693 | §103§112 | Non-Final OA | — | Pending | Jul 08, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEffepharm (Shanghai) Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Hoi Yan Nmn Lee has the most, with 1 of Effepharm (Shanghai) Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.